Intelligence Feed event · Equity · 2026-10-04

    Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial

    Question

    Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial

    Direct answer

    Genmab published clinical efficacy data from its Phase 2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The study recorded an objective response rate of 45.9%, accompanied by a median duration of response of 12.1 months and median progression-free survival of 9.5 months across the cohort.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial”, revision 1, evidence through 2026-10-04. https://marketontology.com/market-events/2026-10-04/genmab-reports-45-9-orr-in-phase-2-platinum-resistant-ovarian-cancer-trial-228d8c

    EQUITY
    Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial
    Genmab published clinical efficacy data from its Phase 2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The study recorded an objective response rate of 45.9%, accompanied by a median duration of response of 12.1 months and median progression-free survival of 9.5 months across the cohort.
    GMAB
    Impact
    72
    OCT 4
    SIG
    92%
    GMAB
    Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial
    Genmab published clinical efficacy data from its Phase 2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The study recorded an objective response rate of 45.9%, accompanied by a median duration of response of 12.1 months and median progression-free survival of 9.5 months across the cohort.
    → Positive Phase 2 oncology trial data enhances pipeline valuation and forward commercialization probabilities for Genmab.
    Impact
    Genmab published clinical efficacy data from its Phase 2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The study recorded an objective response rate of 45.9%, accompanied by a median duration of response of 12.1 months and median progression-free survival of 9.5 months across the cohort.
    Affected
    GMAB
    Transmission
    Positive Phase 2 oncology trial data enhances pipeline valuation and forward commercialization probabilities for Genmab.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GMABbiotech pipeline net present value repricing on positive Phase 2 efficacy dataUp1-5d45.9% ORR and 12.1m mDOR support regulatory pathway and peak revenue forecasts for Rina-S.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month